vTv Therapeutics Inc.
VTVT•NASDAQ•Healthcare•Biotechnology

About vTv Therapeutics

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOPaul Sekhri
Founded2015
IPO DateJuly 30, 2015
Employees23
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock
Share ClassClass A Shares

Contact Information

Websitevtvtherapeutics.com
Phone336 841 0300
Address
3980 Premier Drive, Suite 310 High Point, North Carolina 27265 United States

Corporate Identifiers

CIK0001641489
CUSIP918385105
ISINUS9183852048
EIN47-3916571
SIC2834

Leadership Team & Key Executives

Paul J. Sekhri M.Sc.
Chief Executive Officer, President and Chairman of the Board
Dr. Michael Steven Tung M.B.A., M.D.
Executive Vice President and Chief Financial Officer
Barry K. Brown
Chief Accounting Officer
Dr. Carmen Valcarce Ph.D.
Chief Scientific Officer and Executive Vice President
Elizabeth M. Keiley
Executive Vice President and General Counsel
Richard S. Nelson
Executive Vice President of Corporate Development and Director
Dr. Thomas Strack M.D., Ph.D.
Chief Medical Officer
Martin Lafontaine
Chief Commercial Officer